Tarsus reported Q3 XTENVI net product sales of $194.6 million and raised full-year 2026 sales guidance to $715 million to $730 million. DTC spending will increase to approximately $95 million.
TARS · Tarsus Pharmaceuticals, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64%, but a $668.3 million net loss including $632.2 million of acquired in-process research and development expense.
Tarsus reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64% year-over-year. Net loss widened to $668.3 million, driven by $632.2 million of acquired in-process R&D from the iRenix and Alkeus acquisitions. Cash, cash equivalents and marketable securities were $309.6 million as of September 30, 2026.
Tarsus Pharmaceuticals, Inc. registered up to 2,908,692 shares of common stock for resale by selling stockholders; it will receive no proceeds from their sales.
Tarsus Pharmaceuticals, Inc. registered up to 2,232,144 shares of common stock for resale by selling stockholders, comprising 2,098,519 shares and 133,625 shares issuable upon exercise of pre-funded warrants. The company will receive no proceeds from share sales.
Tarsus Pharmaceuticals reported completion of its Alkeus Pharmaceuticals acquisition on September 10, 2026. Alkeus had an accumulated deficit of $74.3 million at September 30, 2025, raising substantial doubt about its ability to continue as a going concern.